胆囊癌治疗的若干热点问题
摘要
<正>胆囊癌是常见的胆道系统肿瘤之一,发病率列消化系统肿瘤第6位,为(0.5～2.7)/10万。胆囊癌起病隐匿,早期诊断困难,疾病进展迅速,易浸润周围组织和血管,发生淋巴结及远处转移。初诊胆囊癌病人多已晚期,40%～75%的病人合并远处转移,预后极差~([1])。50%～70%的胆囊癌是在初诊为良性疾病行胆囊切除术中及术后发现~([2]),即意外胆囊癌(incidental gallbladder cancer, IGBC)。IGBC的治疗
引文
[1]Zaidi MY,Maithel SK.Updates on gallbladder cancer management[J].Curr Oncol Rep,2018,20(2):21.
[2]Ethun CG,Postlewait LM,Le N,et al.Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival:a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium[J].JAMA Surg,2017,152(2):143-149.
[3]Addeo P,Centonze L,Locicero A,et al.Incidental gallbladder carcinoma discovered after laparoscopic cholecystectomy:identifying patients who will benefit from reoperation[J].J Gastrointest Surg,2018,22(4):606-614.
[4]Creasy JM,Goldman DA,Gonen M,et al.Predicting residual disease in incidental gallbladder cancer:risk stratification for modified treatment strategies[J].J Gastrointest Surg,2017,21(8):1254-1261.
[5]田远虎.腹腔镜胆囊切除术术中或术后发现意外胆囊癌的外科治疗[J].中华外科杂志,2015,53(2):135-139.
[6]Duffy A,Capanu M,Abou-Alfa GK,et al.Gallbladder cancer(GBC):10-year experience at Memorial SloanKettering Cancer Centre(MSKCC)[J].J Surg Oncol,2008,98(7):485-489.
[7]Du J,Yang XW,Wen ZJ,et al.Relationship between prognosis and time interval from cholecystectomy to reoperation in postoperative incidental gallbladder carcinoma[J].Chin Med J(Engl),2018,131(20):2503-2505.
[8]Lee H,Kwon W,Han Y,et al.Optimal extent of surgery for early gallbladder cancer with regard to long-term survival:a meta-analysis[J].J Hepatobiliary Pancreat Sci,2018,25(2):131-141.
[9]段安琪,邱应和,易滨,等.意外胆囊癌在腹腔镜切除术中或术后的处理对策[J].临床和实验医学杂志,2016,15(1):62-64.
[10]Goetze TO,Paolucci V.The prognostic impact of positive lymph nodes in stages T1 to T3 incidental gallbladder carcinoma:results of the German Registry[J].Surg Endosc,2012,26(5):1382-1389.
[11]Sternby Eilard M,Lundgren L,Cahlin C,et al.Surgical treatment for gallbladder cancer-a systematic literature review[J].Scand J Gastroenterol,2017,52(5):505-514.
[12]孙静锋,赵何伟,郑苏文,等.根治性切除及单纯胆囊切除对Ⅱ期胆囊癌疗效的Meta分析[J].中国肿瘤外科杂志,2013,5(1):33-36.
[13]Ito H,Ito K,D'Angelica M,et al.Accurate staging for gallbladder cancer:implications for surgical therapy and pathological assessment[J].Ann Surg,2011,254(2):320-325.
[14]程石.重视意外胆囊癌再次手术的规范[J].临床外科杂志,2017,25(6):423-425.
[15]Shindoh J,de Aretxabala X,Aloia TA,et al.Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer an international multicenter study[J].Ann Surg,2015,261(4):733-739.
[16]Vinuela E,Vega EA,Yamashita S,et al.Incidental gallbladder cancer:residual cancer discovered at oncologic extended resection determines outcome:a report from high-and low-incidence countries[J].Ann Surg Oncol,2017,24(8):2334-2343.
[17]中华医学会外科学分会胆道外科学组.胆囊癌诊断和治疗指南(2015版)[J].中华消化外科杂志,2016,14(3):411-419.
[18]Piccolo G,Piozzi GN.Laparoscopic radical cholecystectomy for primary or incidental early gallbladder cancer:the new rules governing the treatment of gallbladder cancer[J].Gastroenterol Res Pract,2017,2017:8570502.
[19]Berger-Richardson D,Chesney TR,Englesakis M,et al.Trends in port-site metastasis after laparoscopic resection of incidental gallbladder cancer:A systematic review[J].Surgery,2017,161(3):618-627.
[20]Maker AV,Butte JM,Oxenberg J,et al.Is port site resection necessary in the surgical management of gallbladder cancer?[J].Ann Surg Oncol,2012,19(2):409-417.
[21]Ethun CG,Postlewait LM,Le N,et al.Routine port-site excision in incidentally discovered gallbladder cancer is not associated with improved survival:A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium[J].J Surg Oncol,2017,115(7):805-811.
[22]汤朝晖,田孝东,魏妙艳,等.美国癌症联合委员会胆道恶性肿瘤分期系统(第8版)更新解读[J].中国实用外科杂志,2017,37(3):248-254.
[23]Lee W,Jeong CY,Jang JY,et al.Do hepatic-sided tumors require more extensive resection than peritonealsided tumors in patients with T2 gallbladder cancer?Results of a retrospective multicenter study[J].Surgery,2017,162(3):515-524.
[24]汤朝晖,刘颖斌,全志伟.肿瘤分期对胆囊癌术式选择及预后判断临床意义研究[J].中国实用外科杂志2011,31(3):224-227.
[25]Smith-Cohn MA,Gill D,Voorhies BN,et al.Case report:pembrolizumab-induced type 1 diabetes in a patient with metastatic cholangiocarcinoma[J].Immunotherapy,2017,9(10):797-804.
[26]Czink E,Kloor M,Goeppert B,et al.Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer[J].Cold Spring Harb Mol Case Stud,2017,3(5):a001974.
[27]陈亚进,陈贤清.程序性细胞死亡蛋白-1及其配体抑制剂在胆道肿瘤治疗中的现状与前景[J].中华消化外科杂志,2018(3):219-224.
[2]Ethun CG,Postlewait LM,Le N,et al.Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival:a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium[J].JAMA Surg,2017,152(2):143-149.
[3]Addeo P,Centonze L,Locicero A,et al.Incidental gallbladder carcinoma discovered after laparoscopic cholecystectomy:identifying patients who will benefit from reoperation[J].J Gastrointest Surg,2018,22(4):606-614.
[4]Creasy JM,Goldman DA,Gonen M,et al.Predicting residual disease in incidental gallbladder cancer:risk stratification for modified treatment strategies[J].J Gastrointest Surg,2017,21(8):1254-1261.
[5]田远虎.腹腔镜胆囊切除术术中或术后发现意外胆囊癌的外科治疗[J].中华外科杂志,2015,53(2):135-139.
[6]Duffy A,Capanu M,Abou-Alfa GK,et al.Gallbladder cancer(GBC):10-year experience at Memorial SloanKettering Cancer Centre(MSKCC)[J].J Surg Oncol,2008,98(7):485-489.
[7]Du J,Yang XW,Wen ZJ,et al.Relationship between prognosis and time interval from cholecystectomy to reoperation in postoperative incidental gallbladder carcinoma[J].Chin Med J(Engl),2018,131(20):2503-2505.
[8]Lee H,Kwon W,Han Y,et al.Optimal extent of surgery for early gallbladder cancer with regard to long-term survival:a meta-analysis[J].J Hepatobiliary Pancreat Sci,2018,25(2):131-141.
[9]段安琪,邱应和,易滨,等.意外胆囊癌在腹腔镜切除术中或术后的处理对策[J].临床和实验医学杂志,2016,15(1):62-64.
[10]Goetze TO,Paolucci V.The prognostic impact of positive lymph nodes in stages T1 to T3 incidental gallbladder carcinoma:results of the German Registry[J].Surg Endosc,2012,26(5):1382-1389.
[11]Sternby Eilard M,Lundgren L,Cahlin C,et al.Surgical treatment for gallbladder cancer-a systematic literature review[J].Scand J Gastroenterol,2017,52(5):505-514.
[12]孙静锋,赵何伟,郑苏文,等.根治性切除及单纯胆囊切除对Ⅱ期胆囊癌疗效的Meta分析[J].中国肿瘤外科杂志,2013,5(1):33-36.
[13]Ito H,Ito K,D'Angelica M,et al.Accurate staging for gallbladder cancer:implications for surgical therapy and pathological assessment[J].Ann Surg,2011,254(2):320-325.
[14]程石.重视意外胆囊癌再次手术的规范[J].临床外科杂志,2017,25(6):423-425.
[15]Shindoh J,de Aretxabala X,Aloia TA,et al.Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer an international multicenter study[J].Ann Surg,2015,261(4):733-739.
[16]Vinuela E,Vega EA,Yamashita S,et al.Incidental gallbladder cancer:residual cancer discovered at oncologic extended resection determines outcome:a report from high-and low-incidence countries[J].Ann Surg Oncol,2017,24(8):2334-2343.
[17]中华医学会外科学分会胆道外科学组.胆囊癌诊断和治疗指南(2015版)[J].中华消化外科杂志,2016,14(3):411-419.
[18]Piccolo G,Piozzi GN.Laparoscopic radical cholecystectomy for primary or incidental early gallbladder cancer:the new rules governing the treatment of gallbladder cancer[J].Gastroenterol Res Pract,2017,2017:8570502.
[19]Berger-Richardson D,Chesney TR,Englesakis M,et al.Trends in port-site metastasis after laparoscopic resection of incidental gallbladder cancer:A systematic review[J].Surgery,2017,161(3):618-627.
[20]Maker AV,Butte JM,Oxenberg J,et al.Is port site resection necessary in the surgical management of gallbladder cancer?[J].Ann Surg Oncol,2012,19(2):409-417.
[21]Ethun CG,Postlewait LM,Le N,et al.Routine port-site excision in incidentally discovered gallbladder cancer is not associated with improved survival:A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium[J].J Surg Oncol,2017,115(7):805-811.
[22]汤朝晖,田孝东,魏妙艳,等.美国癌症联合委员会胆道恶性肿瘤分期系统(第8版)更新解读[J].中国实用外科杂志,2017,37(3):248-254.
[23]Lee W,Jeong CY,Jang JY,et al.Do hepatic-sided tumors require more extensive resection than peritonealsided tumors in patients with T2 gallbladder cancer?Results of a retrospective multicenter study[J].Surgery,2017,162(3):515-524.
[24]汤朝晖,刘颖斌,全志伟.肿瘤分期对胆囊癌术式选择及预后判断临床意义研究[J].中国实用外科杂志2011,31(3):224-227.
[25]Smith-Cohn MA,Gill D,Voorhies BN,et al.Case report:pembrolizumab-induced type 1 diabetes in a patient with metastatic cholangiocarcinoma[J].Immunotherapy,2017,9(10):797-804.
[26]Czink E,Kloor M,Goeppert B,et al.Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer[J].Cold Spring Harb Mol Case Stud,2017,3(5):a001974.
[27]陈亚进,陈贤清.程序性细胞死亡蛋白-1及其配体抑制剂在胆道肿瘤治疗中的现状与前景[J].中华消化外科杂志,2018(3):219-224.